Browsing by Subject "canine heart"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Delta Opiod Receptor: Parasympathetic Location and Changing Phenotypes in Canine Heart(2007-07-01) Deo, Shekhar H.; James L. Caffrey; H. Fred Downey; Michael SmithDeo, Shekhar H., Delta Opioid Receptor: Parasympathetic Location and Changing Phenotypes in Canine Heart. Doctor of Philosophy (Integrative Physiology), July 23, 112 pp, 4 tables, 24 figures. Delta opioid receptors (DOR) have long been implicated in the complex mechanism of ischemic preconditioning (IPC). Repeated arterial occlusion of the SA node artery in IPC protocol progressively raised the nodal encephalin concentrations and improved vagal transmission during a subsequent extended occlusion. This vagatonic effect was reversed by the DOR-1 antagonist, BNTX. The present thesis tested whether the IPC protocol, the prolonged occlusion or a combination of both was required to demonstrate the vagotonic effect. The study also tested whether the evolution of the vagotonic effect during occlusion might be attributed to erosion of completing vagolytic effects. A progressive improvement in vagal transmission was observed during the IPC protocol. The vagotonic effect was not observed during sham occlusions or during occlusions in animals pretreated with a DOR-1 antagonist. Following the IPC protocol, exogenous MEAP reduced vagal transmission under both normal and occluded conditions. The magnitude of the vagolytic effects was however significantly reduced and eroded further over time compared to time matched shams. The loss of the response was not altered by prior DOR-1. The magnitude of the vagolytic effects was however significantly reduced and eroded further over time compared to time matched shams, however the failure of DOR-1 blockade to slow that process suggests that the PC mediated erosion is independent of receptor activation by DOR-1 agonists. Although DORs are associated with IPC, their precise location remains unconfirmed. DOR and autonomic markers vesicular acetylcholine transporter (VAChT) and tyrosine hydroxylase (TH) were labeled in tissue sections and synaptosomes from canine atrium and SA node. Synapsin I verified the neural character of labeled structures. Acetylcholine and norepinephrine content indicated both cholinergic and adrenergic synaptosomes are present. VAChT and TH signals indicated more than 80% of synapsin positive synaptosomes were cholinergic and less than 8% were adrenergic. Western blots of synaptosomal extracts confirmed by two DOR bands at molecular weights corresponding to reports for DOR monomers and dimmers. The preferential association of DORs with cholinergic nerve terminals supports the hypothesis that post-ganglionic prejunctional DORs regulate local vagal transmission within the heart.Item Met-Enkephalin-Arg-Phe (MERF) and Metabolism of MERF Across the Canine Heart Vascular Bed(2000-08-01) Pearlman, Eric Brian; Barron, Barbara; Gwirtz, Patricia A.; Smith, Michael L.Pearlman, Eric B., Met-Enkephalin-Arg-Phe (MERF) and Metabolism of MERF Across the Canine Heart Vascular Bed. Master of Science (Biomedical Science), August, 2000, 37 pp., 3 tables, 11 figures, references, 20 titles. Methionine enkephalin arginine phenylalanine (MERF) has been shown to be co-stored with catecholamines in vesicles. The catecholamines appear to decrease the degradation rate of 3H-MERF in vitro. The aim of this study is to investigate the spillover and metabolism of MERF across the canine heart vascular bed. I hypothesize that 3H-MERF is either degraded in the plasma or taken up and degraded by the heart. I further hypothesize that the exogenous catecholamine, isoproterenol, inhibits or reduces the rate of MERF degradation. Mongrel dogs were anesthetized and instrumented to record cardiovascular parameters, infuse 3H-MERF, and obtain blood samples across the heart. Blood samples were taken before and after stopping 3H-MERF infusion to evaluate kinetics, show steady state, and test the effect of treatments. Steady state concentration of 3H-MERF was observed after 30 min of infusion. Chromatography separated intact from degraded 3H-MERF. Three experimental groups were used: control, propranolol plus isoproterenol, and propranolol only. Blockade of β-receptors was necessary to prevent changes in coronary blood flow. Propranolol bolus (0.2 mg/kg) was administered IV at 50 min. 3 μg/min isoproterenol or 0.5 ml/min normal saline was infused starting at 70 min until the end of sample collection. The 3H-MERF venous-arterial (V-A) difference prior to treatment was negative, indicating degradation in the plasma or uptake and degradation by the heart. The 75 min V-A difference was used to calculate the effect of the infusions on the degradation or uptake of the 3H-MERF; this value was unchanged by any treatment. Spillover of 3H-MERF was significantly lower in the propranolol + isoproterenol dogs (p [less than] 0.05) compared to propranolol only treatment at 75 min. Heart rate was significantly lower for the propranolol only group compared to control. Blood pressure and change in coronary flow were unchanged. In conclusion, isoproterenol does not affect the metabolism of 3H-MERF across the canine heart vascular bed. Propranolol, however, does increase the intact 3H-MERF in the plasma, but additional β adrenergic blockade agents need to be investigated to determine the mechanism by which this takes place.